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Dose escalation by tomotherapy in non-small cell lung cancer 
- early clinical experiences -
Lee, Chang G.; Lee, Ik J.; Cho, Jae H.; Keum, Ki C.; Kim, Yong B.; 
Yoo, Se W.; Suh, Yang K.; Kim, Song Y.; Kim, Gwi E. 
Yonsei University College of Medicine, Seoul, Korea
Purpose: To evaluate treatment responses, acute toxicities according to 
dose escalation by tomotherapy in non-small cell lung cancer(NSCLC).
Materials and Methods: From May 2006 to January 2007, six patients 
underwent tomotherapy for NSCLC at the Dept. of Radiation Oncol-
ogy, Yonsei Cancer Center. Of the 6 patients, 5 were men and 1 was 
woman. Five patients had adenocarcinoma and 1 had squamous cell 
carcinoma. One patient was stage I, 1 stage IIIA, 4 stage IIIB. To-
motherapy was delivered using Tomotherapy Hi-Art System which 
combines IMRT with a helical delivery pattern to deliver radiation in 
accordance with the prescribed treatment plan. The prescribed dose 
was 75-105 Gy(BED mean 91Gy) to gross tumor volume with 2.5-3 
Gy/fr, 50-55 Gy to clinical target volume with 1.8-2Gy/fr. Induction 
chemotherapy was performed in 5 patients with 3-8 cycles. Concur-
rent chemo-radiotherapy with taxotere or cisplatin was delivered in 5 
patients. 
Results: The response rate after tomotherapy was partial remission in 
5 patients and stable disease in 1. Two patient showed grade II acute 
esophagitis, 1 grade I, 3 grade 0. There was no grade III/IV hemato-
logic toxicity and no symptomatic radiation pneuminitis.
Conclusion: In spite of short clinical experiences, good response rate 
and safe dose escalation without signiﬁcant treatment related acute 
toxicities from sparing of critical normal structures for NSCLC were 
achieved with helical tomotherapy. 
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Early Experience of Helical Tomotherapy for Lung Cancer with 
Multiple Metastatic Lesions
Lee, Ik Jae; Lee, Chang Geol; Cho, Jae Ho; Keum, Ki Chang; Seong, 
Jinsil; Suh, Chang Ok; Kim, Gwi Eon; Jeong, Kyungkeun; Kim, Yong 
Bae 
Yonsei University, College of Medicine, Seoul, Korea
Purpose: The objective of this study is to evaluate efﬁcacy of helical 
tomotherapy for lung cancer with multiple metastatic lesions
Methods and Materials: Nine non-small cell lung cancer patients 
with multiple metastatic lesions were treated with tomotherapy from 
April 2006 to January 2007. Doses of 50-70 Gy with 2.12-6 Gy/frac-
tion for gross target volume were applied. The V20 (the volume of lung 
irradiated to 20 Gy or above) be kept < 30% to maintain a low risk 
of radiation pneumonitis. Among the patients, 5 patients had separate 
metastatic pulmonary tumor nodules in the ipsilateral or contralateral 
nonprimary tumor lobe of the lung, 4 patients had bone metastasis, 1 
patient had brain metastasis, and 1 patient had adrenal gland metastasis. 
Treatment planning was performed using Tomotherapy Hi-Art System, 
version 2.0 (TomoTherapy, WI, USA), applying simultaneously 
integrated boost technique. Subjective pain response to treatment was 
assessed using the Wisconsin Brief Pain Questionnaire, and the morbid-
ity was evaluated by the Common Terminology Criteria for Adverse 
Events v3.0.
Results: Seven patients received various chemotherapeutic regimens 
before tomotherapy. With regard to pain palliative effect, tomotherapy 
